X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with ALEMBIC LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs ALEMBIC LTD - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE ALEMBIC LTD CADILA HEALTHCARE/
ALEMBIC LTD
 
P/E (TTM) x 23.5 58.1 40.3% View Chart
P/BV x 5.9 3.3 179.6% View Chart
Dividend Yield % 0.8 0.3 233.5%  

Financials

 CADILA HEALTHCARE   ALEMBIC LTD
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-17
ALEMBIC LTD
Mar-16
CADILA HEALTHCARE/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs46053 871.2%   
Low Rs30529 1,041.0%   
Sales per share (Unadj.) Rs92.14.7 1,951.6%  
Earnings per share (Unadj.) Rs14.88.8 168.9%  
Cash flow per share (Unadj.) Rs18.59.0 205.2%  
Dividends per share (Unadj.) Rs3.200.15 2,133.3%  
Dividend yield (eoy) %0.80.4 228.9%  
Book value per share (Unadj.) Rs68.027.7 245.2%  
Shares outstanding (eoy) m1,023.74267.03 383.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.28.7 47.7%   
Avg P/E ratio x25.84.7 551.8%  
P/CF ratio (eoy) x20.74.6 454.0%  
Price / Book Value ratio x5.61.5 380.0%  
Dividend payout %21.61.7 1,263.3%   
Avg Mkt Cap Rs m391,58110,962 3,572.3%   
No. of employees `00016.9NA-   
Total wages/salary Rs m15,002238 6,303.4%   
Avg. sales/employee Rs Th5,594.5NM-  
Avg. wages/employee Rs Th890.1NM-  
Avg. net profit/employee Rs Th899.9NM-  
INCOME DATA
Net Sales Rs m94,2951,260 7,481.9%  
Other income Rs m1,286264 487.5%   
Total revenues Rs m95,5811,524 6,271.3%   
Gross profit Rs m19,03683 22,990.3%  
Depreciation Rs m3,75061 6,107.5%   
Interest Rs m4500 150,000.0%   
Profit before tax Rs m16,122285 5,658.8%   
Minority Interest Rs m3380-   
Prior Period Items Rs m02,096 0.0%   
Extraordinary Inc (Exp) Rs m-3-32 9.3%   
Tax Rs m1,2896 21,131.1%   
Profit after tax Rs m15,1682,343 647.4%  
Gross profit margin %20.26.6 307.3%  
Effective tax rate %8.02.1 373.4%   
Net profit margin %16.1185.9 8.7%  
BALANCE SHEET DATA
Current assets Rs m60,2231,689 3,566.0%   
Current liabilities Rs m53,058486 10,912.8%   
Net working cap to sales %7.695.4 8.0%  
Current ratio x1.13.5 32.7%  
Inventory Days Days70217 32.2%  
Debtors Days Days8881 108.8%  
Net fixed assets Rs m72,9841,624 4,493.8%   
Share capital Rs m1,024534 191.7%   
"Free" reserves Rs m68,5765,960 1,150.6%   
Net worth Rs m69,6007,404 940.0%   
Long term debt Rs m24,684104 23,666.3%   
Total assets Rs m152,2078,010 1,900.1%  
Interest coverage x36.8950.7 3.9%   
Debt to equity ratio x0.40 2,517.6%  
Sales to assets ratio x0.60.2 393.8%   
Return on assets %10.329.3 35.1%  
Return on equity %21.831.6 68.9%  
Return on capital %17.931.3 57.3%  
Exports to sales %02.9 0.0%   
Imports to sales %028.9 0.0%   
Exports (fob) Rs mNA37 0.0%   
Imports (cif) Rs mNA364 0.0%   
Fx inflow Rs m21,28037 57,358.5%   
Fx outflow Rs m10,874365 2,979.7%   
Net fx Rs m10,406-328 -3,174.1%   
CASH FLOW
From Operations Rs m13,495346 3,904.8%  
From Investments Rs m-29,103-48 61,140.8%  
From Financial Activity Rs m23,158-301 -7,693.7%  
Net Cashflow Rs m7,556-3 -251,866.7%  

Share Holding

Indian Promoters % 74.8 64.0 116.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 0.2 4,150.0%  
FIIs % 5.9 9.7 60.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 26.1 42.1%  
Shareholders   44,069 54,701 80.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   WYETH LTD  IPCA LABS  JUBILANT LIFE SCIENCES  SUN PHARMA  PIRAMAL ENTERPRISES  

Compare CADILA HEALTHCARE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Lower; Vedanta & Kotak Mahindra Top Losers(Closing)

Indian share markets ended marginally lower on Monday amid weak global cues. The BSE Metal index, however, lost 1.7 amid rising global trade war fears.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (4QFY18); Net Profit Up 50.4%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, CADILA HEALTHCARE has posted a net profit of Rs 6 bn (up 50.4% YoY). Sales on the other hand came in at Rs 33 bn (up 28.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Jun 18, 2018 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 5-YR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS